Share your requirements to help us to customize the report.
   I acknowledge that I have read the Privacy Policy
Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Analyst Support
$5,300
BUY NOW GET FREE SAMPLE

FAQs

Biological Safety Testing Market size was valued at USD 3.73 billion in 2021 and is poised to grow from USD 4.20 billion in 2022 to USD 9.57 billion by 2030, at a CAGR of 12.5% during the forecast period (2023-2030).

These participants are engaging in strategic collaborations with various information technology companies to strengthen their market presence by offering customers improved information management solutions. 'Charles River Laboratories International, Inc. (United States)', 'Lonza Group Ltd. (Switzerland)', 'Merck KGaA (Germany)', 'SGS SA (Switzerland)', 'Eurofins Scientific SE (Luxembourg)', 'Thermo Fisher Scientific Inc. (United States)', 'WuXi AppTec Co., Ltd. (China)', 'bioMérieux SA (France)', 'Nelson Laboratories, LLC (United States)', 'Avance Biosciences (United States)', 'Toxikon Corporation (United States)', 'Pace Analytical Services, LLC (United States)', 'Microbac Laboratories, Inc. (United States)', 'Source BioScience plc (United Kingdom)', 'Creative Bioarray (United States)', 'TÜV SÜD AG (Germany)', 'Pacific BioLabs (United States)', 'Harlan Laboratories Ltd. (United Kingdom)', 'Eurofins BioPharma Product Testing (Belgium)', 'ProPharma Group (United States)'

In vitro testing methods, such as cell-based assays and immunoassays, are gaining popularity due to their advantages over traditional animal-based testing. These methods provide quicker results, reduce the need for animal testing, and offer cost-efficiency, thereby driving their adoption and fueling market growth.

Patient safety has emerged as a critical concern in the healthcare industry, leading to a heightened emphasis on rigorous biological safety testing. The occurrence of adverse events due to contaminated or substandard biological products can have severe consequences for patients. As a result, healthcare providers, regulatory authorities, and manufacturers are prioritizing quality control measures to ensure the safety and well-being of patients. This focus on patient safety drives the demand for comprehensive biological safety testing and promotes market growth.

North America dominates the biological safety testing market, accounting for over of the total revenue. The region's dominance can be attributed to several factors, including a well-established healthcare infrastructure, favorable government initiatives, and a large number of pharmaceutical and biotechnology companies. The United States, in particular, plays a pivotal role in driving market growth, owing to substantial investments in research and development activities. The stringent regulatory framework, enforced by agencies such as the Food and Drug Administration (FDA), further emphasizes the need for comprehensive safety testing, boosting market demand.

Feedback From Our Clients

Global Biological Safety Testing Market

Product ID: SQMIG35J2092

$5,300
BUY NOW GET FREE SAMPLE